Allogene Therapeutics (ALLO) Q2 FY26 earnings call

Allogene Therapeutics is advancing its allogeneic CAR-T platform, focusing on clinical advantages like ready availability and local treatment. The company's strategic shift is yielding results, with Cema-Cel gaining regulatory validation and expanding site activation, while ALLO-316 shows promise in solid tumors despite safety challenges. Rapid enrollment in the ALLO-329 autoimmune trial further underscores the company's execution and program design.